Sanofi (SNY) reported earnings on Thur 6 Feb 20 (b/o)

 ** charts after earnings **

 Sanofi beats by $0.06, reports revs in-line; guides FY20 EPS above consensus

Reports Q4 (Dec) earnings of 1.34 per share, 0.06 better than the S&P Capital IQ Consensus of 1.28; revenues rose 6.8% year/year to 9.61 bln vs the 9.65 bln S&P Capital IQ Consensus.

Co issues upside guidance for FY20, sees EPS of +5% yr/yr to ~6.29 vs. 6.25 S&P Capital IQ Consensus.

Sanofi's brain-penetrant BTK inhibitor meets primary endpoint of Phase 2 trial

The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieved its primary endpoint. In the trial, SAR442168 significantly reduced disease activity associated with multiple sclerosis (MS) as measured by magnetic resonance imaging (MRI). SAR442168 was well tolerated with no new safety findings.

The BTK inhibitor is thought to modulate both adaptive (B-cell activation) and innate (CNS microglial cells) immune cells linked to neuroinflammation in the brain and spinal cord.

Four Phase 3 trials will investigate the effects of SAR442168 on MS relapse rates, disability progression, and underlying central nervous system damage. Phase 3 trials in both relapsing and progressive forms of MS are planned to be initiated in the middle of this year.